News | October 22, 2021
Gland Pharma PAT declines to Rs 302 crore QoQ in Q2FY22
The company’s wide therapeutic portfolio helped to sustain growth despite changing market demand
The company’s wide therapeutic portfolio helped to sustain growth despite changing market demand
It has exercised intellectual property options from IP Group regarding research results generated by the UK Cystic Fibrosis Gene Therapy Consortium, and from Oxford Biomedica regarding their lentiviral vector technology
ICICI Direct gives an update on the 12 companies that it has covered in the healthcare universe. A report
The Amplitude Solution gives laboratories the ability to scale Covid-19 PCR testing and process up to 8,000 samples a day
The first patient dosed with VX-880 demonstrated restoration of insulin production and achieved C-peptide of 560 pmol/L in response to Mixed Meal Tolerance Test (MMTT) at Day 90 visit
First anticipated spinout from the alliance, Circle Therapeutics, to develop novel muscle stem cell therapies for a variety of skeletal muscle disorders
Emkay Research expects Q2FY22 to be a normalised quarter for pharma companies that it tracks. A summary of the report
The consortium envisages carrying out surveillance of important bacterial, viral and parasitic infections of zoonotic as well as transboundary pathogens
_256_384.jpg)
It works by collecting aerosols and identifies the presence of dangerous pathogens using sensitive, specific and rapid detection in near-real time without laboratory analysis
The rolling submission to the U.S. FDA will begin in the fourth quarter of this year
Subscribe To Our Newsletter & Stay Updated
